← All stocks

Keros Therapeutics, Inc.

KROS Net selling
CIK 0001664710 #3893 in the set updated 17 Sep 2026
Bought (1 mo)
$10.27K
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$101.14K
$5.68K on a plan · $0.00 straight out of an exercise
Sold at will
$95.46K
3 of 4 sales
Net
−$90.87K
−$85.19K against sales at will

By person

20 insiders · 5 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Cho Esther
Chief Legal Officer
$46.15K (1)
−$46.15K
35,770
$368.43K
−20.5%
Lerner Lorena Raquel
Chief Scientific Officer
$36.71K (1)
−$36.71K
27,559
$283.86K
−21.3%
Tanini Annita
Corp. Controller & VP, Finance
$12.59K (1)
−$12.59K
45,144
$464.98K
−2.6%
BIENAIME JEAN JACQUES
Director
$10.27K (1)
+$10.27K
19,592
$201.80K
+9,696%
Newton Charles W.
Director
$5.68K (1) scheduled
−$5.68K
12,114
$124.77K
Seehra Jasbir
CHIEF EXECUTIVE OFFICER
440,708
$4.54M
+74.3%
Knowles Julius
Director
113,191
$1.17M
−73.4%
Rovaldi Christopher
Chief Operating Officer
60,000
$618.00K
GORDON CARL L
Director
50,307
$518.16K
−80.6%
ORBIMED ADVISORS LLC entity
Director
45,057
$464.09K
−82.6%
CHYUNG YUNG H.
Chief Medical Officer
44,000
$453.20K
Regnante Keith
CHIEF FINANCIAL OFFICER
39,261
$404.39K
Prener Anne
Director
13,786
$142.00K
GRAY MARY ANN
Director
12,392
$127.64K
Seth Alpna
Director
9,767
$100.60K
Farzan Nima
Director
9,767
$100.60K
Nussbaum Ran
Director
5,250
$54.08K
Kariv Tomer
Director
5,250
$54.08K
Pontifax Management 4 G.P. (2015) Ltd. entity
10% owner
0
$0.00
−100.0%
ADAR1 Capital Management, LLC entity
10% owner
0
$0.00
−100.0%

No percentages here. This company's share count has moved by a factor of 2.1 over the window, from 19,717,533 to 40,615,414 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
BIENAIME JEAN JACQUES
17 Aug 2026
Director
Buy
1,000
$10.27
$10.27K

What was left out

Form 4 filings counted 5
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 1
Sales straight out of an exercise 0
Sales at will 3
Transactions with no price 0
Shares from compensation/vesting 0
History held since 8 Apr 2020